HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data A correction has been published All Versions of this Article: M500140-MCP200v1 5/3/433    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stewart, J. J. Articles by Lin, B. Search for Related Content PubMed PubMed Citation Articles by Stewart, J. J. Articles by Lin, B. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 5:433-443, 2006.
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Proteins Associated with Cisplatin Resistance in Ovarian Cancer Cells Identified by Quantitative Proteomic Technology and Integrated with mRNA Expression Levels^*,S

Jennifer J. Stewart, James T. White, Xiaowei Yan, Steven Collins, Charles W. Drescher^¶, Nicole D. Urban^¶, Leroy Hood and Biaoyang Lin^,||,**

From the The Institute for Systems Biology, Seattle, Washington 98103, Departments of Human Biology and ^¶ Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, and ^|| Shanghai Systems Biomedicine Center, Jiao Tong University, Shanghai 200030, China

Nearly all women diagnosed with ovarian cancer receive combination chemotherapy including cis- or carboplatin. Despite high initial response rates, resistance to cisplatin develops in roughly one-third of women during primary treatment and in all women treated for recurrent disease. ICAT coupled with tandem MS is a quantitative proteomic technique for high throughput protein expression profiling of complex protein mixtures. Using ICAT/MS/MS we profiled the nuclear, cytosolic, and microsomal fractions obtained from IGOV-1 (cisplatin-sensitive) and IGOV-1/CP (cisplatin-resistant) ovarian cancer cell lines. The proteomes of cisplatin-sensitive and -resistant ovarian cancer cells were compared, and protein expression was correlated with mRNA expression profiles. A total of 1117 proteins were identified and quantified. The relative expression of 121 of these varied between the two cell lines. Sixty-three proteins were overexpressed in cisplatin-sensitive, and 58 were over expressed in cisplatin-resistant cells. Examples of proteins at least 5-fold overexpressed in resistant cells and with biological relevance to cancer include cell recognition molecule CASPR3 (13.3-fold), S100 protein family members (8.7-fold), junction adhesion molecule Claudin 4 (7.2-fold), and CDC42-binding protein kinase ß (5.4-fold). Examples of cancer-related proteins at least 5-fold overexpressed in sensitive cells include hepatocyte growth factor inhibitor 1B (13.3-fold) and programmed cell death 6-interacting protein (12.7-fold). The direction of changes in expression levels between proteins and mRNAs were not always in the same direction, possibly reflecting posttranscriptional control of protein expression. We identified proteins whose expression profiles correlate with cisplatin resistance in ovarian cancer cells. Several proteins may be involved in modulating response to cisplatin and have potential as markers of treatment response or treatment targets.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E.-S. A. Arafa, Q. Zhu, B. M. Barakat, G. Wani, Q. Zhao, M. A. El-Mahdy, and A. A. Wani Tangeretin Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Downregulation of Phosphoinositide 3-Kinase/Akt Signaling Pathway Cancer Res., December 1, 2009; 69(23): 8910 - 8917. [Abstract] [Full Text] [PDF]

				I. CADRON, T. VAN GORP, F. AMANT, I. VERGOTE, P. MOERMAN, E. WAELKENS, A. DAEMEN, R. VAN DE PLAS, B. DE MOOR, and R. ZEILLINGER The Use of Laser Microdissection and SELDI-TOF MS in Ovarian Cancer Tissue to Identify Protein Profiles Anticancer Res, April 1, 2009; 29(4): 1039 - 1045. [Abstract] [Full Text] [PDF]

				J. Song, I.-m. Shih, R. Salani, D. W. Chan, and Z. Zhang Annexin XI Is Associated with Cisplatin Resistance and Related to Tumor Recurrence in Ovarian Cancer Patients Clin. Cancer Res., November 15, 2007; 13(22): 6842 - 6849. [Abstract] [Full Text] [PDF]

				B. Sun, J. A. Ranish, A. G. Utleg, J. T. White, X. Yan, B. Lin, and L. Hood Shotgun Glycopeptide Capture Approach Coupled with Mass Spectrometry for Comprehensive Glycoproteomics Mol. Cell. Proteomics, January 1, 2007; 6(1): 141 - 149. [Abstract] [Full Text] [PDF]

				H. Honda, M. J. Pazin, H. Ji, R. P. Wernyj, and P. J. Morin Crucial Roles of Sp1 and Epigenetic Modifications in the Regulation of the CLDN4 Promoter in Ovarian Cancer Cells J. Biol. Chem., July 28, 2006; 281(30): 21433 - 21444. [Abstract] [Full Text] [PDF]